Common types of CLD in the United States are increasing:
Prevalence of nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH) are projected to increase 21% and 63%, respectively, between 2015 and 2030 due to high rates of diabetes and obesity.*3
Incidence of decompensated cirrhosis may increase 168% by 2030, while hepatocellular carcinoma will increase by 137%.*3
As the prevalence of cirrhosis rises, it is expected that cirrhosis complications, including hepatic encephalopathy (HE), will also rise.
The prevalence of minimal HE (MHE) and covert HE (CHE) occurs in as many as 50% of patients with CLD,so guidelines recommend every CLD patient be screened.4
Overt HE (OHE) is estimated to occur in up to 30% to 40% of patients with cirrhosis.4
Screening for CHE is important because it can prognosticate OHE development, indicate poor quality of life, and help identify patients and caregivers who may need to be counseled about the disease.4
In 2018, 37% of hospitalized patients with OHE were readmitted within 30 days.5 Patients who have OHE have a 42% probability of survival after 1 year.†6
HE may affect the patient, the patient’s family, and every one the patient comes in contact with. HE may affect the patient’s ability to work and drive, and has the potential to increase health care costs. It is important to recognize and manage HE to help improve these conditions.7
LIVERHEALTHNOW supports you as you screen CLD patients for HE, with tools for providers and companion patient and caregiver tools to educate patients through screening and diagnosis of HE.
You can add your organization logo to the health tools by following the instructions under the Customize button next to each tool. You can also save your tools to your Favorites for easier access.